Head-to-head · Value Score
Trimi Health vs Zealthy
Two GLP-1 deals, scored on the same six factors. Trimi Health lands a Value Score of 89, Zealthy a 54. Here's who gives you the honest lower price — and where each one bites back.
Trimi Health
#3 · Grade A · Great Deal
Est. first month
$99/mo
Save ~93% vs brand-nameZealthy
#382 · Grade C · Watch List
Est. first month
From $286/mo (starting dose, plus a separate fee, compounded)
Save ~79% vs brand-nameThe verdict
Trimi Health takes it on Value Score, 89 to 54 — an est. $99/mo first month, with no teaser step-up baked in. Zealthy isn't out of it: Shoppers who want not currently recommended — listed for transparency and reader awareness only.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | Trimi Health | Zealthy |
|---|---|---|
| Value Score | 89 (A) | 54 (C) |
| Est. first month | $99/mo | From $286/mo (starting dose, plus a separate fee, compounded) |
| Save vs brand-name | ~93% | ~79% |
| Semaglutide | $99/mo | From $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | $125/mo | From $351/mo (starting dose, plus a separate fee, compounded) |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Watch |
| Coverage | All 50 states | 34 states |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
Trimi Health
The ultra-budget pick: two-digit semaglutide and a $125 tirzepatide — one of the lowest flat tirz stickers on the whole board — shipped to all 50 states.
Why it's a deal
- Ultra-budget on both molecules — $99 semaglutide and a class-low $125 tirzepatide, flat with no teaser step-up
- Tirzepatide at $125/mo undercuts most of the flat-fee field on the priciest molecule
- Nationwide 50-state reach, so the low price isn't gated to a handful of states
The fine print
- Not LegitScript-certified — do your own pharmacy diligence before you buy on price alone
- Compounded injectable only — no FDA-approved brand-name or oral/sublingual route
- Newer brand with a thin public track record
Zealthy
Zealthy (legal entity FitRX, LLC, recently renamed to Gronk Inc.) offers compounded semaglutide and tirzepatide via an asynchronous telehealth model.
Why it's a deal
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
The fine print
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores Trimi Health is ranked on the Trimi Health alternatives board, and the same list for the other side is on alternatives to Zealthy.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.